74 filings
8-K
UBX
Unity Biotechnology Inc
21 Jun 24
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
UBX
Unity Biotechnology Inc
14 May 24
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results
5:00pm
8-K
UBX
Unity Biotechnology Inc
15 Apr 24
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
7:00am
8-K
UBX
Unity Biotechnology Inc
20 Mar 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:15pm
8-K
UBX
Unity Biotechnology Inc
13 Nov 23
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
4:05pm
8-K
85i10dxer1 cl7
13 Nov 23
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
7:00am
8-K
cgr0w20a
27 Sep 23
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
7:05am
8-K
qf4d74ngo59g
6 Sep 23
Termination of a Material Definitive Agreement
4:05pm
8-K
06eqfkve3pzs8
8 Aug 23
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results
4:04pm
8-K
frtgudwcn 6vb8
23 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
vbkjjsxwa4xf5cw2gyd
9 May 23
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
4:10pm
8-K/A
m154 b0hufraxhxg3f4
28 Apr 23
Departure of Directors or Certain Officers
4:05pm
8-K
ubtr9sd 2d8bx03bt
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
41gdhfo zvkpjzdl5n
11 Apr 23
Departure of Directors or Certain Officers
4:06pm
8-K
am8viw lpyj0
27 Mar 23
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
7:00am
8-K
hhpi im3pfunv2rupg
17 Mar 23
Other Events
5:14pm
8-K
coy7h5if2vnrg
15 Mar 23
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
4:25pm
8-K
h7bmh2hq7310dh v8i
10 Mar 23
Regulation FD Disclosure
8:00pm
8-K
4kq5fr85 8w
8 Nov 22
UNITY Biotechnology, Inc. Reports Third Quarter 2022
4:09pm
8-K
7xkn77jvqb
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am